Please login to the form below

Not currently logged in
Email:
Password:

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm
Merck KGgA

Merck KGgA has appointed Laszlo Radvanyi as senior vice president and head of research in immuno-oncology.

Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the aim to deliver personalized treatments for patients.

Before joining Merck KGgA, Radvanyi served as chief scientific officer at Lion Biotechnologies based in Florida where he was responsible for developing new technologies to product next-generation TILs for tumor indications including lung, cervical and breast cancer.

Luciano Rossetti, head of global research and development, said: “We are honoured to have Laszio join Merck KGaA. His vast experience across the field of immuno-oncology research is very impressive.

“His expertise and fresh perspective will add significant value to our early-stage immuno-oncology portfolio including combination and biomarker strategies for avelumab and other clinical candidates, as we endeavour to bring new therapeutic options to patients living with cancer.”

4th November 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics